Large-scale hepatitis C combating campaigns in Egypt and Georgia; past, current and future challenges.

Hepatitis C virus (HCV) infection is a major worldwide problem which should be adequately combated. This review summarizes two successful model programs to eradicate Hepatitis C in two countries; Egypt and Georgia. Egypt tops the list of nations affected by HCV, and Georgia is ranked among other countries with huge HCV burden. Currently, both countries are on their ambitious way to making history and completely eliminate Hepatitis C virus infections. The first comprehensive approach to reduce the burden of hepatitis C and associated diseases in Egypt was achievable with the formulation of the National Committee for Control of Viral Hepatitis (NCCVH) in 2006. Assisted by international and national stalk holders, Georgia started its nation- wide HCV fighting program in 2015. Elements of programs mostly addressed in both countries included simplifying and improving access to the package of diagnosis and care- providing effective, affordable or free of charge treatment- issuing, applying and regularly updating practice guidelines- improving surveillance, monitoring, and research focusing specifically on the risky groups- emphasizing infection control (IC) - encouraging patient and community engagement and increasing public and political commitment. Interventions are still going on to eradicate HCV infection in Egypt by 2030 and in Georgia by 2020. Lessons gained from this program can educate comparable activities in different nations and help control the worldwide epidemic of viral hepatitis.

[1]  J. Ward,et al.  The Role of Screening and Treatment in National Progress Toward Hepatitis C Elimination — Georgia, 2015–2016 , 2017, MMWR. Morbidity and mortality weekly report.

[2]  A. Gomaa,et al.  Hepatitis C infection in Egypt: prevalence, impact and management strategies , 2017, Hepatic medicine : evidence and research.

[3]  I. Waked,et al.  National treatment programme of hepatitis C in Egypt: Hepatitis C virus model of care , 2017, Journal of viral hepatitis.

[4]  A. Fontanet,et al.  The prevalence of hepatitis C virus infection in Egypt 2015: implications for future policy on prevention and treatment , 2016, Liver international : official journal of the International Association for the Study of the Liver.

[5]  J. Ward,et al.  National Progress Toward Hepatitis C Elimination - Georgia, 2015-2016. , 2016, MMWR. Morbidity and mortality weekly report.

[6]  W. Doss,et al.  Antiviral treatment prioritization in HCV-infected patients with extrahepatic manifestations - An Egyptian perspective. , 2016, Journal of advanced research.

[7]  S. Alim,et al.  Effect of Sofosbuvir, brand drug (Sovaldi) versus generic (MPIViropack) in treating Chronic HCV infection among Egyptian patients , 2015 .

[8]  J. Ward,et al.  Launch of a Nationwide Hepatitis C Elimination Program — Georgia, April 2015 , 2015, MMWR. Morbidity and mortality weekly report.

[9]  H. Razavi,et al.  Economic burden of hepatitis C in Egypt: the future impact of highly effective therapies , 2015, Alimentary pharmacology & therapeutics.

[10]  M. Gogia Assessing Risky Behavior of PWIDs in Georgia - Comparable Analyses of Two Samples , 2015 .

[11]  F. Amer,et al.  Epidemiology of Hepatitis C Virus Infection in Egypt. , 2015 .

[12]  T. Elbaz,et al.  New era for management of chronic hepatitis C virus using direct antiviral agents: A review , 2014, Journal of advanced research.

[13]  P. André,et al.  Recent evidence of underestimated circulation of hepatitis C virus intergenotypic recombinant strain RF2k/1b in the Rhône-Alpes region, France, January to August 2014: implications for antiviral treatment. , 2014, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[14]  del RioCarlos,et al.  Mortality and Causes of Death Among HIV-Infected Individuals in the Country of Georgia: 1989–2012 , 2014 .

[15]  H. Razavi,et al.  The current and future disease burden of chronic hepatitis C virus infection in Egypt. , 2014, Arab journal of gastroenterology : the official publication of the Pan-Arab Association of Gastroenterology.

[16]  B. Milani,et al.  Pathway to affordable quality assured sources of pegylated interferon alpha for treating hepatitis C , 2013 .

[17]  C. Treloar,et al.  Understanding barriers to hepatitis C virus care and stigmatization from a social perspective. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[18]  A. V. Burdakov,et al.  Electronic integrated disease surveillance system and pathogen asset control system. , 2012, The Onderstepoort journal of veterinary research.

[19]  M. Hassany,et al.  The future for the treatment of genotype 4 chronic hepatitis C , 2012, Liver international : official journal of the International Association for the Study of the Liver.

[20]  Gamal Esmat,et al.  Progress toward prevention and control of hepatitis C virus infection--Egypt, 2001-2012. , 2012, MMWR. Morbidity and mortality weekly report.

[21]  M. Topuridze,et al.  Nosocomial Infections in Tbilisi, Georgia: A Retrospective Study of Microbiological Data from 4 Major Tertiary Care Hospitals , 2011, Infection Control & Hospital Epidemiology.

[22]  L. Kostrikis,et al.  Near-Full Genome Characterisation of Two Natural Intergenotypic 2k/1b Recombinant Hepatitis C Virus Isolates , 2011, Advances in virology.

[23]  F. Sugauchi,et al.  Detection of hepatitis C virus natural recombinant RF1_2k/1b strain among intravenous drug users in Uzbekistan , 2008, Hepatology research : the official journal of the Japan Society of Hepatology.

[24]  S. Pol,et al.  FIB‐4: An inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest , 2007, Hepatology.

[25]  I. Moreau,et al.  Serendipitous identification of natural Intergenotypic recombinants of hepatitis C in Ireland , 2006, Virology Journal.

[26]  F. Mahoney,et al.  Evolution of infection control in Egypt: achievements and challenges. , 2006, American journal of infection control.

[27]  K. Nelson,et al.  Prevalence of Hepatitis C, HIV, and Risk Behaviors for Blood-Borne Infections: A Population-Based Survey of the Adult Population of T'bilisi, Republic of Georgia , 2006, Journal of Urban Health.

[28]  C. del Rio,et al.  Risk Factors for Hepatitis C Virus Infection among Blood Donors in Georgia , 2003, European Journal of Epidemiology.

[29]  F. Mahoney,et al.  Overview of injection practices in two governorates in Egypt , 2003, Tropical medicine & international health : TM & IH.

[30]  Malla R Rao,et al.  Further evidence for association of hepatitis C infection with parenteral schistosomiasis treatment in Egypt , 2002, BMC infectious diseases.

[31]  Olga Kalinina,et al.  A Natural Intergenotypic Recombinant of Hepatitis C Virus Identified in St. Petersburg , 2002, Journal of Virology.

[32]  F. Miller,et al.  High HCV prevalence in Egyptian blood donors , 1992, The Lancet.